The AMPK-dependent activation of FOXO3a transcriptional program in metabolic stress conditions causes tumor growth inhibition, both in vitro and in vivo [132], suggesting that pharmacological manipulation of the AMPK-FOXO3a axis is an interesting approach for cancer treatment. The gene discussed is FOXO3; the disease is cancer.